Search

Your search keyword '"Ciccone, Lucia Pia"' showing total 20 results
Start Over Author "Ciccone, Lucia Pia" Publication Year Range Last 3 years
20 results on '"Ciccone, Lucia Pia"'

4. Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719)

Author

Francolini, Giulio, Detti, Beatrice, Di Cataldo, Vanessa, Garlatti, Pietro, Aquilano, Michele, Allegra, Andrea, Lucidi, Sara, Cerbai, Cecilia, Ciccone, Lucia Pia, Salvestrini, Viola, Stocchi, Giulia, Guerrieri, Barbara, Visani, Luca, Loi, Mauro, Desideri, Isacco, Mangoni, Monica, Meattini, Icro, and Livi, Lorenzo

Published
2022
Full Text
View/download PDF

5. Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis

Author

Francolini, Giulio, Jereczek-Fossa, Barbara Alicja, Di Cataldo, Vanessa, Simontacchi, Gabriele, Marvaso, Giulia, Gandini, Sara, Corso, Federica, Ciccone, Lucia Pia, Zerella, Maria Alessia, Gentile, Piercarlo, Bianciardi, Federico, Allegretta, Sara, Detti, Beatrice, Desideri, Isacco, D’Angelillo, Rolando Maria, Masi, Laura, Ingrosso, Gianluca, Di Staso, Mario, Mazzeo, Ercole, Trippa, Fabio, Lohr, Frank, Bruni, Alessio, and Livi, Lorenzo

Published
2022
Full Text
View/download PDF

6. Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275)

Author

Francolini, Giulio, Loi, Mauro, Ciccone, Lucia Pia, Detti, Beatrice, Di Cataldo, Vanessa, Pinzani, Pamela, Salvianti, Francesca, Salvatore, Giulia, Sottili, Mariangela, Santini, Costanza, Frosini, Giulio, Visani, Luca, Burchini, Luca, Mattioli, Chiara, Allegra, Andrea Gaetano, Valzano, Marianna, Cerbai, Cecilia, Aquilano, Michele, Salvestrini, Viola, Desideri, Isacco, Mangoni, Monica, Meattini, Icro, and Livi, Lorenzo

Published
2022
Full Text
View/download PDF

7. Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833)

Author

Desideri, Isacco, Lucidi, Sara, Francolini, Giulio, Meattini, Icro, Ciccone, Lucia Pia, Salvestrini, Viola, Valzano, Marianna, Morelli, Ilaria, Angelini, Lucia, Scotti, Vieri, Bonomo, Pierluigi, Greto, Daniela, Terziani, Francesca, Becherini, Carlotta, Visani, Luca, and Livi, Lorenzo

Published
2022
Full Text
View/download PDF

8. 780: Proton radiotherapy in meningioma and hemangiopericytoma: a monocentric clinical report.

Author

Ciccone, Lucia Pia, Riva, Giulia, Goodyear, Christina Amanda, Fontana, Giulia, Seetha, Sithin Thulasi, Molinelli, Silvia, Bazani, Alessia, Bonora, Maria, Ronchi, Sara, Barcellini, Amelia, Franzetti, Jessica, Camarda, Anna Maria, Rotondi, Marco, Chalaszczyk, Agnieszka, Ingargiola, Rossana, Lillo, Sara, Colombo, Francesca, Vitolo, Viviana, Fiore, Maria Rosaria, and Vischioni, Barbara

Subjects
*MENINGIOMA, *PROTONS, *RADIOTHERAPY
Published
2024
Full Text
View/download PDF

12. Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial

Author

Camerini, Andrea, primary, Del Conte, Alessandro, additional, Pezzuto, Aldo, additional, Scotti, Vieri, additional, Facchinetti, Francesco, additional, Ciccone, Lucia Pia, additional, Perna, Marco, additional, Sartori, Giulia, additional, Puccetti, Cheti, additional, Ricci, Alberto, additional, Santo, Antonio, additional, Tiseo, Marcello, additional, and Amoroso, Domenico, additional

Published
2022
Full Text
View/download PDF

13. Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes

Author

Tibaldi, Carmelo, primary, Mazzoni, Francesca, additional, Scotti, Vieri, additional, Vasile, Enrico, additional, Pozzessere, Daniele, additional, Stasi, Irene, additional, Camerini, Andrea, additional, Federici, Francesca, additional, Meoni, Giulia, additional, Caparello, Chiara, additional, Turrini, Marianna, additional, Rossi, Virginia, additional, Ciccone, Lucia Pia, additional, Pecora, Irene, additional, Fantechi, Beatrice, additional, Antonuzzo, Lorenzo, additional, Giannarelli, Diana, additional, and Baldini, Editta, additional

Published
2022
Full Text
View/download PDF

14. Use of an Alfa-lipoic, Methylsulfonylmethane, Boswellia Serrata and Bromelain Dietary Supplement (OPERA®) for Aromatase Inhibitors-related Arthralgia Management (AIA): a prospective phase II trial (NCT04161833)

Author

Desideri, Isacco, primary, Lucidi, Sara, additional, Francolini, Giulio, additional, Meattini, Icro, additional, Ciccone, Lucia Pia, additional, Salvestrini, Viola, additional, Valzano, Marianna, additional, Morelli, Ilaria, additional, Angelini, Lucia, additional, Scotti, Vieri, additional, Bonomo, Pierluigi, additional, Greto, Daniela, additional, Terziani, Francesca, additional, Becherini, Carlotta, additional, Visani, Luca, additional, and Livi, Lorenzo, additional

Published
2022
Full Text
View/download PDF

15. ARTO trial-(NCT03449719): Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration-resistant prostate cancer undergoing I line treatment with abiraterone acetate.

Author

Francolini, Giulio, primary, Detti, Beatrice, additional, Di Cataldo, Vanessa, additional, Caini, Saverio, additional, Alitto, Anna Rita, additional, Parisi, Silvana, additional, Demofonti, Chiara, additional, Bruni, Alessio, additional, Ingrosso, Gianluca, additional, Timon, Giorgia, additional, Allegra, Andrea, additional, Aquilano, Michele, additional, Ciccone, Lucia Pia, additional, Salvestrini, Viola, additional, Frosini, Giulio, additional, Cerbai, Cecilia, additional, Desideri, Isacco, additional, Meattini, Icro, additional, Mangoni, Monica, additional, and Livi, Lorenzo, additional

Published
2022
Full Text
View/download PDF

16. PRIMERA trial (NCT04188275), early survival results from a prospective trial exploring impact of circulating tumor cell detection in castrate resistant prostate cancer patients undergoing abiraterone or enzalutamide I line treatment.

Author

Francolini, Giulio, primary, Loi, Mauro, additional, Ciccone, Lucia Pia, additional, Mangoni, Monica, additional, Detti, Beatrice, additional, Di Cataldo, Vanessa, additional, Aquilano, Michele, additional, Allegra, Andrea, additional, Pinzani, Pamela, additional, Salvianti, Francesca, additional, Cerbai, Cecilia, additional, Burchini, Luca, additional, Frosini, Giulio, additional, Mattioli, Chiara, additional, Salvestrini, Viola, additional, Guerrieri, Barbara, additional, Salvatore, Giulia, additional, Sottili, Mariangela, additional, Desideri, Isacco, additional, and Livi, Lorenzo, additional

Published
2022
Full Text
View/download PDF

19. Charged particle radiotherapy for thyroid cancer. A systematic review.

Author

Ciccone LP, Franzetti J, Bonora M, Ronchi S, Camarda AM, Charalampopoulou A, Facoetti A, Bazani A, Magro G, Vischioni B, Locati LD, Licitra L, Sauerwein WAG, and Orlandi E

Abstract

The role of external beam radiotherapy (EBRT) in thyroid cancer (TC) remains contentious due to limited data. Retrospective studies suggest adjuvant EBRT benefits high-risk differentiated thyroid cancer (DTC) and limited-stage anaplastic thyroid carcinoma (ATC), enhancing locoregional control and progression-free survival when combined with surgery and chemotherapy. Intensity-modulated radiotherapy (IMRT) and particle therapy (PT), including protons, carbon ions, and Boron Neutron Capture Therapy (BNCT), represent advances in TC treatment. Following PRISMA guidelines, we reviewed 471 studies from January 2002 to January 2024, selecting 14 articles (10 preclinical, 4 clinical). Preclinical research focused on BNCT in ATC mouse models, showing promising local control rates. Clinical studies explored proton, neutron, or photon radiotherapy, reporting favorable outcomes and manageable toxicity. While PT shows promise supported by biological rationale, further research is necessary to clarify its role and potential combination with systemic treatments in TC management., Competing Interests: Declaration of Competing Interest None declared, (Copyright © 2024 Elsevier B.V. All rights reserved.)

Published
2024
Full Text
View/download PDF

20. Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Author

Camerini A, Mazzoni F, Scotti V, Tibaldi C, Sbrana A, Calabrò L, Caliman E, Ciccone LP, Bernardini L, Graziani J, Grosso MA, Chella A, Allegrini G, Amoroso D, and Baldini E

Abstract

Background: There are currently few data about the safety and effectiveness of chemotherapy for patients with metastatic non-small-cell lung cancer (NSCLC) who have progressed from prior immunotherapy. Methods: Data from patients with consecutive stage IIIB-IV, ECOG performance status (PS) 0-2, non-small-cell lung cancer (NSCLC) treated with combination or single-agent chemotherapy following progression on an earlier immunotherapy regimen were retrospectively gathered. Recorded were baseline attributes, outcome metrics, and toxicities. The neutrophil/lymphocyte (N/L) ratio's predictive usefulness was examined through an exploratory analysis. Results: The analysis comprised one hundred subjects. The adeno/squamous carcinoma ratio was 77%/23%, the M/F ratio was 66%/34%, the ECOG PS was 0/1/≥2 47%/51%/2%, and the median PD-L1 expression was 50% (range 0-100). The median age was 67 (range 39-81) years. Prior immunotherapy included a single-agent treatment in 83% of cases, with pembrolizumab use being prevalent, and a median N/L ratio of four prior to chemotherapy. The overall median time-to-progression on previous immunotherapy was 6 months. After immunotherapy, just 33% of subjects underwent chemotherapy. A median of 4 (range 1-16) cycles of chemotherapy were administered; platinum doublets (primarily carboplatin) were delivered in only 31% of cases, vinorelbine accounted for 25%, taxanes for 25%, and gemcitabine for 8%. The median clinical benefit was 55%, while the overall response rate was 21%. The median overall survival was 5 months (range 1-22) and the median time to progression was 4 months (range 1-17). Subgroups with low and high N/L ratios were compared, but there was no discernible difference in survival. Conclusions: After immunotherapy, a small percentage of patients with advanced NSCLC had chemotherapy. Following immunotherapy advancement, chemotherapy demonstrated a moderate level of therapeutic effectiveness; no adverse concerns were noted. The effectiveness of chemotherapy following immunotherapy was not predicted by the baseline N/L ratio.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results